myelodysplastic syndromes

Summary

Summary: Conditions in which the bone marrow shows qualitative and quantitative changes suggestive of a preleukemic process, but having a chronic course that does not necessarily terminate as acute leukemia.

Top Publications

  1. ncbi The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
    James W Vardiman
    Department of Pathology, University of Chicago, IL, USA
    Blood 114:937-51. 2009
  2. ncbi Revised international prognostic scoring system for myelodysplastic syndromes
    Peter L Greenberg
    Hematology Division, Stanford University Cancer Center, Stanford, CA 94305, USA
    Blood 120:2454-65. 2012
  3. ncbi Frequent pathway mutations of splicing machinery in myelodysplasia
    Kenichi Yoshida
    Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Nature 478:64-9. 2011
  4. ncbi Mutation in TET2 in myeloid cancers
    Francois Delhommeau
    INSERM U790, Institut Gustave Roussy, Villejuif, France
    N Engl J Med 360:2289-301. 2009
  5. pmc Clinical effect of point mutations in myelodysplastic syndromes
    Rafael Bejar
    Department of Medicine, Harvard Medical School and Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 364:2496-506. 2011
  6. pmc Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
    Pierre Fenaux
    Hopital Avicenne, Universite Paris XIII, Bobigny, France
    Lancet Oncol 10:223-32. 2009
  7. pmc Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts
    E Papaemmanuil
    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    N Engl J Med 365:1384-95. 2011
  8. ncbi The World Health Organization (WHO) classification of the myeloid neoplasms
    James W Vardiman
    Department of Pathology, University of Chicago, IL 60637, USA
    Blood 100:2292-302. 2002
  9. ncbi Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes
    Gorica Nikoloski
    Department of Laboratory Medicine, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands
    Nat Genet 42:665-7. 2010
  10. pmc Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes
    Timothy A Graubert
    Department of Internal Medicine, Division of Oncology, Washington University, St Louis, Missouri, USA
    Nat Genet 44:53-7. 2012

Detail Information

Publications354 found, 100 shown here

  1. ncbi The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
    James W Vardiman
    Department of Pathology, University of Chicago, IL, USA
    Blood 114:937-51. 2009
    ....
  2. ncbi Revised international prognostic scoring system for myelodysplastic syndromes
    Peter L Greenberg
    Hematology Division, Stanford University Cancer Center, Stanford, CA 94305, USA
    Blood 120:2454-65. 2012
    ..System (IPSS) is an important standard for assessing prognosis of primary untreated adult patients with myelodysplastic syndromes (MDS)...
  3. ncbi Frequent pathway mutations of splicing machinery in myelodysplasia
    Kenichi Yoshida
    Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Nature 478:64-9. 2011
    b>Myelodysplastic syndromes and related disorders (myelodysplasia) are a heterogeneous group of myeloid neoplasms showing deregulated blood cell production with evidence of myeloid dysplasia and a predisposition to acute myeloid leukaemia, ..
  4. ncbi Mutation in TET2 in myeloid cancers
    Francois Delhommeau
    INSERM U790, Institut Gustave Roussy, Villejuif, France
    N Engl J Med 360:2289-301. 2009
    The myelodysplastic syndromes and myeloproliferative disorders are associated with deregulated production of myeloid cells. The mechanisms underlying these disorders are not well defined.
  5. pmc Clinical effect of point mutations in myelodysplastic syndromes
    Rafael Bejar
    Department of Medicine, Harvard Medical School and Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 364:2496-506. 2011
    b>Myelodysplastic syndromes are clinically heterogeneous disorders characterized by clonal hematopoiesis, impaired differentiation, peripheral-blood cytopenias, and a risk of progression to acute myeloid leukemia...
  6. pmc Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
    Pierre Fenaux
    Hopital Avicenne, Universite Paris XIII, Bobigny, France
    Lancet Oncol 10:223-32. 2009
    Drug treatments for patients with high-risk myelodysplastic syndromes provide no survival advantage...
  7. pmc Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts
    E Papaemmanuil
    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    N Engl J Med 365:1384-95. 2011
    b>Myelodysplastic syndromes are a diverse and common group of chronic hematologic cancers. The identification of new genetic lesions could facilitate new diagnostic and therapeutic strategies.
  8. ncbi The World Health Organization (WHO) classification of the myeloid neoplasms
    James W Vardiman
    Department of Pathology, University of Chicago, IL 60637, USA
    Blood 100:2292-302. 2002
    ....
  9. ncbi Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes
    Gorica Nikoloski
    Department of Laboratory Medicine, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands
    Nat Genet 42:665-7. 2010
    In myelodysplastic syndromes (MDS), deletions of chromosome 7 or 7q are common and correlate with a poor prognosis. The relevant genes on chromosome 7 are unknown. We report here that EZH2, located at 7q36...
  10. pmc Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes
    Timothy A Graubert
    Department of Internal Medicine, Division of Oncology, Washington University, St Louis, Missouri, USA
    Nat Genet 44:53-7. 2012
    b>Myelodysplastic syndromes (MDS) are hematopoietic stem cell disorders that often progress to chemotherapy-resistant secondary acute myeloid leukemia (sAML)...
  11. ncbi Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes
    Luca Malcovati
    Department of Hematology, University of Pavia, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, 27100 Pavia, Italy
    J Clin Oncol 25:3503-10. 2007
    The aims of this study were to identify the most significant prognostic factors in myelodysplastic syndromes (MDS) taking into account both their values at clinical onset and their changes in time and to develop a dynamic model for ..
  12. ncbi Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1794-803. 2006
    Aberrant DNA methylation, which results in leukemogenesis, is frequent in patients with myelodysplastic syndromes (MDS) and is a potential target for pharmacologic therapy...
  13. pmc Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
    M J Walter
    Department of Internal Medicine, Division of Oncology, Washington University, St Louis, MO 63110, USA
    Leukemia 25:1153-8. 2011
    Alterations in DNA methylation have been implicated in the pathogenesis of myelodysplastic syndromes (MDS), although the underlying mechanism remains largely unknown...
  14. pmc Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia
    Marc H G P Raaijmakers
    Center for Regenerative Medicine, Massachusetts General Hospital and Harvard Medical School CPZN, USA
    Nature 464:852-7. 2010
    ..Furthermore, primary stromal dysfunction can result in secondary neoplastic disease, supporting the concept of niche-induced oncogenesis...
  15. ncbi Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
    R Itzykson
    Service d Hématologie Clinique Hôpital Avicenne, Assistance Publique Hopitaux de Paris AP HP, Universite Paris 13, Bobigny, France
    Leukemia 25:1147-52. 2011
    ..Response duration and overall survival were, however, comparable in the MUT and WT groups. In higher risk MDS and AML with low blast count, TET2 status may be a genetic predictor of response to AZA, independently of karyotype...
  16. ncbi Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype
    Daniel T Starczynowski
    British Columbia Cancer Agency Research Centre, Vancouver, British Columbia, Canada
    Nat Med 16:49-58. 2010
    ..Thus, inappropriate activation of innate immune signals in HSPCs phenocopies several clinical features of 5q- syndrome...
  17. ncbi Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group
    Torsten Haferlach
    MLL Munich Leukemia Laboratory, Munich, Germany
    J Clin Oncol 28:2529-37. 2010
    ..The Microarray Innovations in Leukemia study assessed the clinical utility of gene expression profiling as a single test to subtype leukemias into conventional categories of myeloid and lymphoid malignancies...
  18. ncbi Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia
    Véronique Gelsi-Boyer
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR891 Inserm, Institut Paoli Calmettes, France
    Br J Haematol 145:788-800. 2009
    The myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal haematological diseases characterized by ineffective haematopoiesis and predisposition to acute myeloid leukaemia (AML). The pathophysiology of MDSs remains unclear...
  19. ncbi Myelodysplastic syndromes
    Stephen D Nimer
    Division of Hematologic Oncology and Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Blood 111:4841-51. 2008
    ..Our understanding of the pathogenesis of the myelodysplastic syndromes (MDSs) has lagged behind, at least in part, because they represent a more heterogeneous group of ..
  20. pmc Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations
    Britta Will
    Albert Einstein College of Medicine, Bronx, NY, USA
    Blood 120:2076-86. 2012
    ..This study demonstrates that stem and progenitor cells in MDS are characterized by stage-specific expansions and contain epigenetic and genetic alterations...
  21. pmc Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes
    Rafael Bejar
    Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 30:3376-82. 2012
    A subset of patients with myelodysplastic syndromes (MDS) who are predicted to have lower-risk disease as defined by the International Prognostic Scoring System (IPSS) demonstrate more aggressive disease and shorter overall survival than ..
  22. ncbi A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
    Pierre Fenaux
    Hopital Avicenne, Assistance Publique Hopitaux de Paris, Universite Paris XIII, Bobigny, France
    Blood 118:3765-76. 2011
    ..patients with International Prognostic Scoring System Low-/Intermediate-1-risk del5q31 myelodysplastic syndromes. Patients received lenalidomide 10 mg/day on days 1-21 (n = 69) or 5 mg/day on days 1-28 (n = 69) of 28-..
  23. ncbi Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
    Raphael Itzykson
    Clinique Hôpital Avicenne, Assistance Publique Hopitaux de Paris, Paris, France
    Blood 117:403-11. 2011
    ..In conclusion, routine tests can identify subgroups of patients with distinct prognosis with AZA treatment...
  24. ncbi Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 111:1060-6. 2008
    ..Patients with relapsed or refractory leukemias or myelodysplastic syndromes (MDS) and untreated patients who were not candidates for chemotherapy were eligible...
  25. pmc Unraveling the molecular pathophysiology of myelodysplastic syndromes
    Rafael Bejar
    Brigham and Women s Hospital, Karp Research Building, CHRB 05 211, 1 Blackfan Cir, Boston, MA 02115, USA
    J Clin Oncol 29:504-15. 2011
    Somatically acquired genetic abnormalities lead to the salient features that define myelodysplastic syndromes (MDS): clonal hematopoiesis, aberrant differentiation, peripheral cytopenias, and risk of progression to acute myeloid leukemia...
  26. ncbi Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome
    Andres O Soriano
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 110:2302-8. 2007
    ..VPA blood levels were higher in responders (P < .005). In conclusion, the combination studied is safe and has significant clinical activity. This clinical trial was registered at www.clinicaltrials.gov as no. NCT00326170...
  27. ncbi Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia
    Marco Tartaglia
    Department of Pediatrics, Mount Sinai School of Medicine, New York, New York, USA
    Nat Genet 34:148-50. 2003
    ..Functional analyses documented that the two most common mutations in PTPN11 associated with JMML caused a gain of function...
  28. pmc Aberrant DNA methylation is a dominant mechanism in MDS progression to AML
    Ying Jiang
    Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland Clinic, OH 44195, USA
    Blood 113:1315-25. 2009
    b>Myelodysplastic syndromes (MDSs) are clonal hematologic disorders that frequently represent an intermediate disease stage before progression to acute myeloid leukemia (AML)...
  29. ncbi Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
    Bruce D Cheson
    Department of Hematology Oncology, Georgetown University Hospital, Washington, DC, USA
    Blood 108:419-25. 2006
    The myelodysplastic syndromes (MDSs) are heterogeneous with respect to clinical characteristics, pathologic features, and cytogenetic abnormalities. This heterogeneity is a challenge for evaluating response to treatment...
  30. pmc The helix-loop-helix transcription factor TWIST is dysregulated in myelodysplastic syndromes
    Xiang Li
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 116:2304-14. 2010
    Patients with low-grade myelodysplastic syndromes (MDS) show high levels of tumor necrosis factor α (TNFα) and up-regulation of apoptosis in the marrow...
  31. pmc Clonal diversity of recurrently mutated genes in myelodysplastic syndromes
    M J Walter
    Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St Louis, MO, USA
    Leukemia 27:1275-82. 2013
    ..The VAFs of recurrently mutated genes did not fully recapitulate the clonal architecture defined by WGS, suggesting that comprehensive sequencing may be required to accurately assess the clonal status of recurrently mutated genes in MDS...
  32. pmc Transcriptional regulation of miR-10a/b by TWIST-1 in myelodysplastic syndromes
    Xiang Li
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Haematologica 98:414-9. 2013
    ..These data support a role for miR10a/10b in the regulation of apoptosis in myelodysplastic syndrome and suggest the TWIST-1/miR10a/b-axis as a therapeutic target in myelodysplastic syndrome...
  33. ncbi Loss of the tumor suppressor BAP1 causes myeloid transformation
    Anwesha Dey
    Department of Physiological Chemistry, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
    Science 337:1541-6. 2012
    ..A BAP1 catalytic mutation found in a MDS patient implies that BAP1 loss of function has similar consequences in mice and humans...
  34. ncbi Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes
    Felicitas Thol
    Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Carl Neuberg Str 1, 30625 Hannover, Germany
    J Clin Oncol 29:2499-506. 2011
    ..To study the incidence and prognostic impact of mutations in Additional sex comb-like 1 (ASXL1) in a large cohort of patients with myelodysplastic syndrome (MDS)...
  35. ncbi CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)
    Shahram Y Kordasti
    Department of Hematological Medicine, King s College London, Rayne Institute, 123 Coldharbour Lane, London, UK
    Blood 110:847-50. 2007
    ..032). Our data suggest that CD4+ Treg expansion is a feature of high-risk MDS and progression to aggressive subtypes of the disease...
  36. pmc MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation
    Maria E Figueroa
    Department of Medicine Hematology Oncology Division, Weill Cornell Medical College, New York, NY 10065, USA
    Blood 114:3448-58. 2009
    ..Several of these diseases, such as myelodysplastic syndromes (MDSs), are responsive to DNA methyltransferase inhibitors...
  37. pmc Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy
    Hagop M Kantarjian
    Leukemia Department, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Blood 116:3163-70. 2010
    ..efficacy and safety of romiplostim, a thrombopoietin mimetic, in patients with low- or intermediate-risk myelodysplastic syndromes (MDS) receiving azacitidine therapy...
  38. ncbi Innate immune signaling in the myelodysplastic syndromes
    Daniel T Starczynowski
    Genome Sciences Centre, British Columbia Cancer Research Centre, 675 West 10th Avenue, Vancouver, BC, Canada
    Hematol Oncol Clin North Am 24:343-59. 2010
    b>Myelodysplastic syndromes (MDS) are heterogeneous clonal hematologic malignancies characterized by cytopenias caused by ineffective hematopoiesis and propensity to progress to acute myeloid leukemia...
  39. ncbi Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Rese
    Michael Lubbert
    Albert Ludwigs University, Freiburg, Germany
    J Clin Oncol 29:1987-96. 2011
    ..To compare low-dose decitabine to best supportive care (BSC) in higher-risk patients with myelodysplastic syndrome (MDS) age 60 years or older and ineligible for intensive chemotherapy...
  40. pmc Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes
    Asaka Kondo
    Division of Hematology, Department of Medicine, Nippon Medical School, 1 1 5 Sendagi, Bunkyo ku, Tokyo, Japan
    Blood 116:1124-31. 2010
    During disease progression in myelodysplastic syndromes (MDS), clonal blasts gain a more aggressive nature, whereas nonclonal immune cells become less efficient via an unknown mechanism...
  41. ncbi Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients
    Sergio Matarraz
    Centro de Investigación del Cáncer Instituto de Biología Molecular y Celular del Cáncer CSIC USAL, Servicio General de Citometría and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain
    Cytometry B Clin Cytom 78:154-68. 2010
    A heterogeneous spectrum of immunophenotypic abnormalities have been reported in myelodysplastic syndromes (MDS)...
  42. pmc Integrative analysis of next generation sequencing for small non-coding RNAs and transcriptional regulation in Myelodysplastic Syndromes
    Dominik Beck
    Bioengineering and Bioinformatics Program, Department of Pathology, The Methodist Hospital Research Institute, Weill Cornell Medical College, Houston, TX, 77030, USA
    BMC Med Genomics 4:19. 2011
    b>Myelodysplastic Syndromes (MDSS) are pre-leukemic disorders with increasing incident rates worldwide, but very limited treatment options...
  43. ncbi Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes
    Felicitas Thol
    Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
    Blood 119:3578-84. 2012
    Mutations in genes of the splicing machinery have been described recently in myelodysplastic syndromes (MDS)...
  44. ncbi Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes
    Frederik Damm
    Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif, France
    Blood 119:3211-8. 2012
    ....
  45. pmc Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*
    Valeria Santini
    Azienda Ospedaliera Universitaria Careggi, Florence, Italy
    Eur J Haematol 85:130-8. 2010
    ..We present previously unpublished data from two large phase III trials describing common adverse events (AEs) associated with azacitidine and methods to manage them...
  46. pmc Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)
    Sham Mailankody
    Multiple Myeloma Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Blood 118:4086-92. 2011
    ..51-fold (95% confidence interval: 8.19-15.74) increased risk of acute myeloid leukemia (AML)/myelodysplastic syndromes (MDS); risk was very similar before/after 1995 and 2000, respectively. MGUS patients had an 8.01-fold (5...
  47. ncbi Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS)
    I Kotsianidis
    Department of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece
    Leukemia 23:510-8. 2009
    ..In myelodysplastic syndromes (MDS), immune deregulation and autoimmunity in the early stages might lead to ineffective hematopoiesis ..
  48. ncbi A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies
    Francis Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Clin Cancer Res 12:4628-35. 2006
    ..LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines. In this phase I study, LBH589 was administered i.v. as a 30-minute infusion on days 1 to 7 of a 21-day cycle...
  49. ncbi IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome
    Shahram Y Kordasti
    Department of Haematological Medicine, King s College London, The Rayne Institute, London, UK
    Br J Haematol 145:64-72. 2009
    ..The 'unfavourable' Th17:Tregs ratio in low risk MDS may explain the higher risk of autoimmunity and the improved response to immune suppression in patients with low risk MDS compared to those with high risk disease...
  50. ncbi Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making
    Luca Malcovati
    Division of Hematology, IRCCS, Policlinico San Matteo, 27100 Pavia, Italy
    J Clin Oncol 23:7594-603. 2005
    ..evaluate the prognostic value of the WHO proposal, to assess the role of the main prognostic factors in myelodysplastic syndromes (MDSs) classified into WHO subgroups, and to estimate mortality (standardized mortality ratio [SMR]) and ..
  51. ncbi Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms
    Steven D Gore
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21287, USA
    Cancer Res 66:6361-9. 2006
    ..The promising percentage of major hematologic responses justifies the testing of such combinations in prospective randomized trials...
  52. pmc Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis
    Hideki Makishima
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
    Blood 119:3203-10. 2012
    b>Myelodysplastic syndromes (MDSs) are chronic and often progressive myeloid neoplasms associated with remarkable heterogeneity in the histomorphology and clinical course. Various somatic mutations are involved in the pathogenesis of MDS...
  53. ncbi TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression
    Martin Jadersten
    Center for Experimental Hematology M54, Karolinska Institutet, Karolinska University Hospital Huddinge, SE 141 86 Stockholm, Sweden
    J Clin Oncol 29:1971-9. 2011
    To determine the frequency of TP53 mutations and the level of p53 protein expression by immunohistochemistry (IHC) in low-risk myelodysplastic syndromes (MDS) with del(5q) and to assess their impact on disease progression.
  54. pmc Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias
    Julien Rocquain
    Laboratoire d Oncologie Moleculaire, UMR891 Inserm, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, Marseille, France
    BMC Cancer 10:401. 2010
    ..Gene mutation is an important mechanism of myeloid leukemogenesis. However, the number and combination of gene mutated in myeloid malignancies is still a matter of investigation...
  55. pmc Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia
    Cynthia L Fisher
    Department of Zoology, University of British Columbia, Vancouver, BC, Canada
    Blood 115:38-46. 2010
    ....
  56. ncbi CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes
    Leonidas Benetatos
    Department of Hematology, University Hospital of Ioannina, Niarchos Avenue, 45500 Ioannina, Greece
    Leuk Res 34:148-53. 2010
    ..Our findings suggest that these genes are abnormally methylated in AML and MDS patients, and methylation of MEG3 confers worse overall prognosis. The MEG3 methylation status may serve as a useful biomarker in leukemia...
  57. ncbi International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report
    Janet D Rowley
    Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Genes Chromosomes Cancer 33:331-45. 2002
  58. ncbi TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis
    Austin G Kulasekararaj
    Department of Haematological Medicine, King s College London, School of Medicine, London, UK
    Br J Haematol 160:660-72. 2013
    ..The relatively common occurrence of these mutations in two different prognostic spectrums of MDS, i.e. isolated 5q- and CK with -5/5q-, possibly implies two different mechanistic roles for TP53 protein...
  59. ncbi New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge
    Julie Schanz
    University of Gottingen, Gottingen, Germany
    J Clin Oncol 30:820-9. 2012
    The karyotype is a strong independent prognostic factor in myelodysplastic syndromes (MDS)...
  60. ncbi Decreased phosphorylation of protein kinase B and extracellular signal-regulated kinase in neutrophils from patients with myelodysplasia
    Gwenny M Fuhler
    Division of Hematology, Department of Medicine, University Hospital Groningen, The Netherlands
    Blood 101:1172-80. 2003
    ..Our results indicate that the reduced priming of neutrophil ROS production in MDS patients might be caused by a disturbed convergence of the fMLP and GM-CSF signaling routes...
  61. ncbi Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes
    Lubomir Sokol
    Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA lubomir org
    Br J Haematol 153:24-32. 2011
    The myelodysplastic syndromes (MDS) display both haematological and biological heterogeneity with variable leukaemia potential...
  62. ncbi Therapy with azanucleosides for myelodysplastic syndromes
    Alfonso Quintas-Cardama
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Nat Rev Clin Oncol 7:433-44. 2010
    Azanucleosides constitute the core therapy in the management of myelodysplastic syndromes (MDS), and have altered the treatment paradigm of MDS, previously dominated by supportive care strategies...
  63. ncbi In vitro deprivation of CD8(+)CD57(+)T cells promotes the malignant growth of bone marrow colony cells in patients with lower-risk myelodysplastic syndrome
    Zhang Zheng
    Department of Hematology, Sixth Hospital Affiliated to Shanghai Jiaotong University, PR China
    Exp Hematol 38:677-84. 2010
    ..We investigated the effect of activated CD8(+)T (CD8(+)CD57(+)) lymphocytes on colony formation (in particular, malignant colony formation) during MDS in vitro...
  64. ncbi Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options
    Charlotte Marie Niemeyer
    Department of Paediatrics and Adolescent Medicine, University of Freiburg, Freiburg, Germany
    Br J Haematol 140:610-24. 2008
    b>Myelodysplastic syndromes (MDS) and the mixed myelodysplastic/myeloproliferative disorder juvenile myelomonocytic leukaemia (JMML) are rare haematopoietic stem cell diseases in children...
  65. ncbi The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes
    Azra Raza
    Myelodysplastic Syndromes Center, Columbia University Medical Center, Milstein Hospital Building, 6N 435, 177 Fort Washington Avenue, New York, New York 10032, USA
    Nat Rev Cancer 12:849-59. 2012
    b>Myelodysplastic syndromes (MDS) are malignant clonal disorders of haematopoietic stem cells and their microenvironment, affecting older individuals (median age ∼70 years)...
  66. pmc Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies
    Ramon V Tiu
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute Center, Cleveland, OH, USA
    Blood 117:4552-60. 2011
    ..b>Myelodysplastic syndromes (MDSs) and related cancers share recurrent chromosomal defects and molecular lesions that predict ..
  67. pmc Cytogenetic features in myelodysplastic syndromes
    Detlef Haase
    Department of Hematology and Oncology, Georg August University, Robert Koch Str 40, 37075, Gottingen, Germany
    Ann Hematol 87:515-26. 2008
    b>Myelodysplastic syndromes (MDS) comprise a group of bone marrow diseases characterized by profound heterogeneity in morphologic presentation, clinical course, and cytogenetic features...
  68. ncbi The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England
    Karen J Phekoo
    Department of Haematological Medicine, Kings Healthcare NHS Trust, Denmark Hill, London, SE5 9RS, UK
    Haematologica 91:1400-4. 2006
    There is a paucity of epidemiological data on chronic myeloproliferative disorders and myelodysplastic syndromes (MDS), while subtypes of acute myeloid leukemia (AML) are rarely defined...
  69. ncbi Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions
    Leonidas Benetatos
    Department of Hematology, University Hospital of Ioannina, Niarchos Avenue, 45500 Ioannina, Greece
    Ann Hematol 90:1037-45. 2011
    ..As such, SNK/PLK2 could represent a potential pathogenetic factor, although additional studies are necessary to verify its exact role in disease pathogenesis...
  70. ncbi Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes
    Efstratios Katsoulidis
    Robert H Lurie Comprehensive Cancer Center and Division of Hematology Oncology, Northwestern University Medical School, Chicago, IL 60611, USA
    Cancer Res 65:9029-37. 2005
    ..inhibition of p38 reverses the hematopoietic defects seen in bone marrows from patients with myelodysplastic syndromes (MDS) and the anemia of chronic disease...
  71. pmc Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation
    Marina Bousquet
    Institut National de Santé et de Recherche Médicale, U563, Centre de Physiopathologie de Toulouse Purpan, 31300 Toulouse, France
    J Exp Med 205:2499-506. 2008
    Most chromosomal translocations in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) involve oncogenes that are either up-regulated or form part of new chimeric genes...
  72. ncbi Functional disturbance of marrow stromal microenvironment in the myelodysplastic syndromes
    S Tauro
    Department of Molecular and Cellular Pathology, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, UK
    Leukemia 16:785-90. 2002
    The potential contribution of abnormal marrow stromal function to ineffective haemopoiesis in the myelodysplastic syndromes is unclear...
  73. pmc Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)
    Luca Malcovati
    Department of Hematology Oncology, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
    Haematologica 96:1433-40. 2011
    Anemia is an established negative prognostic factor in myelodysplastic syndromes but the relationship between its degree and clinical outcome is poorly defined...
  74. ncbi Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells
    S Geyh
    Department of Hematology, University of Duesseldorf, Duesseldorf, Germany
    Leukemia 27:1841-51. 2013
    Ineffective hematopoiesis is a major characteristic of myelodysplastic syndromes (MDS) causing relevant morbidity and mortality...
  75. pmc Establishment of a xenograft model of human myelodysplastic syndromes
    Yukari Muguruma
    Research Center for Regenerative Medicine, Division of Hematopoiesis, Tokai University School of Medicine, Isehara, Japan
    Haematologica 96:543-51. 2011
    ..and gain competitive advantages over normal hematopoiesis, we established a murine xenograft model harboring bone marrow cells from patients with myelodysplastic syndromes or acute myeloid leukemia with myelodysplasia-related changes.
  76. ncbi Progression of myelodysplasia to acute lymphoblastic leukaemia: implications for disease biology
    Patricia Disperati
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, Toronto, Ont, Canada
    Leuk Res 30:233-9. 2006
    ..We review the cancer stem cell model and its application to these disorders, and discuss the implications of the rarity of transformation of MDS to ALL for the biology of MDS and the pathogenesis of ALL...
  77. ncbi Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology
    Andrea Pellagatti
    Leukaemia Research Fund Molecular Haematology Unit, Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, UK
    Br J Haematol 125:576-83. 2004
    The myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal disorders of the haematopoietic stem cell and primarily involve cells of the myeloid lineage...
  78. pmc Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis
    Anupama Narla
    Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    Blood 118:2296-304. 2011
    ..Our findings indicate that dexamethasone and lenalidomide promote different stages of erythropoiesis and support the potential clinical utility of combination therapy for patients with bone marrow failure...
  79. ncbi Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes
    Emiliano Fabiani
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, L go A Gemelli, Rome, Italy
    Leuk Res 33:1068-71. 2009
    ..the impact of genomic polymorphisms of 9 genes involved in xenobiotics detoxification and DNA repair in myelodysplastic syndromes (MDS)...
  80. ncbi Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes
    Akira Matsuda
    Division of Hematology, Department of Internal Medicine, Saitama Medical School, 38 Morohongo, Moroyama, Iruma gun, Saitama, 350 0495, Japan
    Blood 106:2633-40. 2005
    ..In conclusion, our results indicate that the clinical features of Japanese patients with FAB-RA differ from those of German patients...
  81. pmc Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
    Luca Malcovati
    Department of Hematology and Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S Matteo, and
    Blood 122:2943-64. 2013
    ..A number of new agents are being developed for which the available evidence is not sufficient to recommend routine use. The inclusion of patients into prospective clinical trials is strongly recommended. ..
  82. pmc Computerized texture analysis of atypical immature myeloid precursors in patients with myelodysplastic syndromes: an entity between blasts and promyelocytes
    Joyce R Vido
    Department of Internal Medicine, Faculty of Medical Sciences, State University of Campinas, Rua Tessalia Vieira de Camargo 126, 13083 887, Campinas, Brazil
    Diagn Pathol 6:93. 2011
    Bone marrow (BM) blast count is an essential parameter for classification and prognosis of myelodysplastic syndromes (MDS)...
  83. ncbi Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study
    U Germing
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Dusseldorf, Dusseldorf, Germany
    Leukemia 26:1286-92. 2012
    b>Myelodysplastic syndromes (MDS) with del(5q) are considered to have a benign course of the disease...
  84. ncbi Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes
    James M Foran
    Mayo Clinic, Jacksonville, Florida 32224, USA
    Am J Med 125:S6-13. 2012
    b>Myelodysplastic syndromes (MDS) comprise a group of underrecognized hematologic clonal malignancies with variable propensity for leukemic transformation that can present a diagnostic challenge because they lack hallmark symptoms...
  85. pmc Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
    U Platzbecker
    Medical Clinic and Polyclinic I, University Hospital Carl Gustav Carus Technical University of Dresden, Dresden, Germany
    Leukemia 26:381-9. 2012
    ..a sensitive donor chimerism analysis of CD34(+) blood cells to pre-empt relapse in patients with CD34(+) myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT)...
  86. ncbi A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome
    Azra Raza
    Columbia University Medical Center, Milstein Hospital Bldg, 6N 435, 177 Fort Washington Avenue, New York, NY 10032, USA
    Cancer 118:2138-47. 2012
    ..This study evaluated 2 extended dose schedules of oral ezatiostat in 89 heavily pretreated patients with low to intermediate-1 risk myelodysplastic syndrome (MDS)...
  87. pmc Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C
    Pierre Fenaux
    Hopital Avicenne, Assistance Publique Hôpitaux de Paris and Paris 13 University, Bobigny, France
    Br J Haematol 149:244-9. 2010
    ..When analyzed per patient year of drug exposure, azacitidine treatment was associated with fewer grade 3-4 cytopenias and shorter hospitalisation time than LDara-C in these higher-risk MDS patients...
  88. pmc Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment
    Tony Navas
    Scios Inc, Fremont, CA, USA
    Leuk Lymphoma 49:1963-75. 2008
    b>Myelodysplastic syndromes (MDS) are common causes of ineffective hematopoiesis and cytopenias in the elderly...
  89. ncbi Engraftment of NOD/SCID-beta2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome
    Eleni Thanopoulou
    Terry Fox Laboratory, BC Cancer Agency, 601 West 10th Ave, Vancouver, BC, Canada V5Z 1L3
    Blood 103:4285-93. 2004
    ..the investigation of some human hematopoietic malignancies, but application of this approach to the myelodysplastic syndromes (MDSs) has proven difficult...
  90. pmc Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia
    Christopher N Hahn
    Department of Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, South Australia, Australia
    Nat Genet 43:1012-7. 2011
    ..Identification of such predisposing genes to familial forms of MDS and AML is critical for more effective diagnosis and prognosis, counseling, selection of related bone marrow transplant donors and development of therapies...
  91. ncbi Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset
    Claudio Fozza
    Institute of Hematology, University of Sassari, Sassari, Italy
    Exp Hematol 37:947-55. 2009
    Immune dysregulation plays a role in the pathophysiology of myelodysplastic syndromes (MDS), as T-cell clones seem to be involved in the inhibition of hematopoietic precursors...
  92. pmc NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes
    Peter L Greenberg
    Stanford Comprehensive Cancer Center, USA
    J Natl Compr Canc Netw 9:30-56. 2011
    ..116,119,120,128,129) Progress toward improving management of MDS has occurred over the past few years, and more advances are anticipated using these guidelines as a framework for coordination of comparative clinical trials...
  93. pmc Hypomethylating agents and other novel strategies in myelodysplastic syndromes
    Guillermo Garcia-Manero
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Box 428, 1515 Holcombe Blvd, PO Box 301402, Houston, TX 77025, USA
    J Clin Oncol 29:516-23. 2011
    Over the last decade, treatment approaches for patients with myelodysplastic syndromes (MDS) have improved significantly. Treatment of MDS is tailored to the specific risk characteristics of the patient...
  94. ncbi Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines
    V Santini
    Functional Unit of Haematology, AOU Careggi, University of Florence, Firenze, Italy
    Leuk Res 34:1576-88. 2010
    ..publication of the previous Italian Society of Haematology (SIE) practice guidelines for management of myelodysplastic syndromes (MDS), novel disease-modifying treatments have been introduced and the SIE commissioned an update...
  95. ncbi Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Am J Hematol 87:692-701. 2012
    ..MDS occurs more frequently in older male and in individuals with prior exposure to cytotoxic therapy...
  96. pmc Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase
    Li Zhou
    Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Cancer Res 71:955-63. 2011
    Even though myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis, the molecular alterations that lead to marrow failure have not been well elucidated...
  97. pmc Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes
    Lewis R Silverman
    Department of Medicine Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Cancer 117:2697-702. 2011
    ....
  98. pmc DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes
    Elizabeth A Griffiths
    Sidney Kimmel Comprehensive Cancer Centre, Johns Hopkins Hospital, Baltimore, MD 21231, USA
    Semin Hematol 45:23-30. 2008
    ..Combination therapy offers the possibility of hematologic improvement and remission to myelodysplastic patients with previously untreatable disease...
  99. ncbi The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes
    Apostolia Maria Tsimberidou
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:1605-13. 2008
    ..and other cytokines are involved in the pathogenesis of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), but their prognostic significance in these diseases is unknown...
  100. ncbi Microarray-based comparative genomic hybridization of cancer targets reveals novel, recurrent genetic aberrations in the myelodysplastic syndromes
    Kathryn A Kolquist
    Sacred Heart Medical Center, Spokane, WA, USA
    Cancer Genet 204:603-28. 2011
    The myelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders characterized by ineffective hematopoiesis, cytopenias, and a risk of transformation to acute myeloid leukemia (AML)...
  101. pmc Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries
    Christopher R Cogle
    Division of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL 32610 0278, USA
    Blood 117:7121-5. 2011
    The myelodysplastic syndromes (MDSs) are hematologically diverse hematopoietic stem cell malignancies primarily affecting older individuals. The incidence of MDS in the United States is estimated at 3...

Research Grants62

  1. NF1 GENE IN MYELOID LEUKEMIA AND CYTOKINE SIGNALING
    DAVID LARGAESPADA; Fiscal Year: 2002
    DESCRIPTION: (adapted from the investigator's abstract) Treatment of childhood myelodysplastic syndromes (MDS) as well as chronic and acute myeloid leukemia (CML and AML) remains disappointing compared with well known advances in the ..
  2. Chemical modulators of Tet-family proteins
    Anjana Rao; Fiscal Year: 2010
    ..ii) TET1 is an MLL partner in acute myeloid and lymphoid leukemia (AML, ALL), and TET2 is implicated in myelodysplastic syndromes and AML...
  3. Molecular Pathogenesis of MDS and CMML
    Jaroslaw P Maciejewski; Fiscal Year: 2013
    ..PUBLIC HEALTH RELEVANCE: Myelodysplastic syndromes (MDS) is a heterogeneous group of bone marrow failure states characterized by dysplastic hematopoiesis, ..
  4. Characterization of Genetic Abnormalities in MDS and Their Clinical Impact
    Rafael Bejar; Fiscal Year: 2013
    ..career development plan that seeks to characterize the broad range of mutations present in patients with myelodysplastic syndromes while establishing an academic career as a physician scientist in the field of hematology...
  5. Training/Research Center-Bone Marrow Failure Syndromes
    Jaroslaw P Maciejewski; Fiscal Year: 2013
    ..NARRATIVE: Myelodysplastic syndromes (MDS) is a heterogeneous group of bone marrow failure states characterized by dysplastic hematopoiesis, ..
  6. System for Rapid Generation of Aptamers for Transplant Therapies
    KAREN QIAN; Fiscal Year: 2010
    ..option for many patients with hematologic malignancies and solid tumors such as acute myeloid leukemia, myelodysplastic syndromes, chronic myeloid leukemia, systemic mastocytosis and breast cancer...
  7. Mechanisms linking RAS signals to disordered hematopoiesis and myeloid neoplasia
    BENJAMIN BRAUN; Fiscal Year: 2013
    ..Thus, they have features of both myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN)...
  8. Cyclin E Regulation in Normal and Neoplastic Hematopoiesis
    ALEXANDER C MINELLA; Fiscal Year: 2013
    ..These features are characteristics of hematopoietic cells of patients with early-stage myelodysplastic syndromes (MDS)...
  9. Modulation of T cell Homeostasis in Myelodysplastic Syndrome (MDS)
    Javier Pinilla; Fiscal Year: 2012
    b>Myelodysplastic syndromes (MDS) are characterized by incompetent hematopoiesis that leads to single or multi-lineage peripheral cytopenias with the development of acute myeloid leukemia (AML) in approximately 30-40% of cases...
  10. The Role of the APC Tumor Suppressor Gene in Hematopoiesis and Leukemogenesis
    Zhijian Qian; Fiscal Year: 2013
    ..The myelodysplastic syndromes (MDS) are clonal disorders of hematopoietic stem cells (HSCs), characterized by ineffective ..
  11. Targeting the ROS-p38 MAPK Pathway as a Novel Strategy for Stem Cell Expansion
    GAVIN YONG WANG; Fiscal Year: 2012
    ..in the pathogenesis of a variety of hematopoietic disorders, including Franconi anemia (FA) and myelodysplastic syndromes (MDS)...
  12. Role of TET proteins in myeloid malignancies
    Anjana Rao; Fiscal Year: 2013
    ..Simultaneously, several labs reported that TET2 mutations are frequently associated with myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) and myeloid malignancies such as chronic myelomonocytic ..
  13. IEX-1 as a potential biomarker for early detection of myelodysplastic syndromes
    Mei X Wu; Fiscal Year: 2012
    ..a potential of IEX-1 (Immediate Early responsive gene X-1) as a biomarker for the early diagnosis of myelodysplastic syndromes (MDS) or its progression to acute myeloid leukemia (AML)...
  14. The role of Dock4 in normal and aberrant erythropoiesis
    Amittha Wickrema; Fiscal Year: 2013
    ..Moreover, in conditions such as myelodysplastic syndromes (MDS), where anemia is the most common presentation and predominant cause of morbidity, the focus has ..
  15. THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES
    Oliver W Press; Fiscal Year: 2013
    ..refine and extend this treatment for acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS) and lymphomas by targeting radionuclides to neoplastic cells using monoclonal antibodies (Ab) ..
  16. Investigation of the Role of BAP1 in Normal and Malignant Hematopoiesis
    LINDSAY MARIE LAFAVE; Fiscal Year: 2013
    ..BAP1 has been found to be mutated and downregulated in human myelodysplastic syndromes (MDS) consistent with BAP1 functioning as a novel tumor suppressor in the hematopoietic compartment...
  17. Myelodysplastic Syndromes: Patterns of Care and Outcomes
    Xiaomei Ma; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): The myelodysplastic syndromes (MDS) are a group of clonal proliferative bone marrow disorders that result in dysmyelopoiesis and peripheral blood cytopenias...
  18. 2012 CRTI Summer Workshop
    Mark Crowther; Fiscal Year: 2012
    ..all areas of hematology, including the hematological malignancies (leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, myeloproliferative neoplasms) and non-malignant hematology (bleeding and clotting disorders and ..
  19. Transcriptional Control of Stroma Dependent Apoptosis in MDS
    A MARIO Q MARCONDES; Fiscal Year: 2013
    ..The proposal is aimed at elucidating the pathophysiology of the myelodysplastic syndromes (MDS). A prominent characteristic of MDS is dysregulation of programmed cell death (apoptosis)...
  20. System Biology Approach for Signaling Transduction Study of Complex Phenotypes
    Youli Zu; Fiscal Year: 2012
    ..We will use the four myelodysplastic syndromes (MDS) phenotypes as the prototype of disease to test the performance of this package by integrating high-..
  21. Th1/Th17 Macrophage Interactions in Cutaneous GVHD
    JONATHAN STUART SERODY; Fiscal Year: 2013
    ..the most active therapy for patients with high risk acute leukemia, low grade lymphoid malignancies, myelodysplastic syndromes and is increasingly used in patients with relapsed lymphoid malignancies...
  22. GENETICS OF MYELODYSPLASTIC SYNDROMES
    Matthew J Walter; Fiscal Year: 2013
    ..this project is to identify and characterize genes that contribute to the development and progression of myelodysplastic syndromes (MDS)...
  23. Specialized Program Of Research Excellence (SPORE) in Leukemia
    Daniel C Link; Fiscal Year: 2013
    ..is a highly dynamic translational cancer research program that focuses specifically on leukemias and myelodysplastic syndromes (MDS)...
  24. Third Bone Marrow Failure Disease Scientific Symposium
    Richard M Stone; Fiscal Year: 2012
    ..Foundation 2012 Bone Marrow Failure Disease Scientific Symposium Project Abstract Aplastic anemia (AA), myelodysplastic syndromes (MDS), and paroxysmal nocturnal hemoglobinuria (PNH) are rare diseases that result in bone marrow ..
  25. DNA Replication and Genome-Wide Demethylation in Erythropoiesis
    Merav Socolovsky; Fiscal Year: 2013
    ..Indeed, genome-wide aberrant DNA methylation was recently found in the refractory anemias classified as myelodysplastic syndromes (MDS), where demethylation therapy is successful...
  26. Modeling Multi-step Leukemogenesis Nf1 and Kras Mutant Mice
    JENNIFER LAUCHLE; Fiscal Year: 2009
    ..In contrast, myelodysplastic syndromes (MDSs) are usually associated with low blood cell counts and aberrant bone marrow morphology, while ..
  27. Role of AhR During Megakaryopoiesis
    STEPHAN CADET LINDSEY; Fiscal Year: 2011
    ..treating Mk and platelet disorders such as essential thrombocytopenia, refractory thrombocytopenia in myelodysplastic syndromes, megakaryoblastic leukemia, and thrombocythemia...
  28. Myelodysplastic Syndromes: Previous Exposures, Survival, and Quality of Life
    Xiaomei Ma; Fiscal Year: 2010
    ..The myelodysplastic syndromes (MDS) are a group of clonal proliferative bone marrow disorders resulting in dysmyelopoiesis and ..
  29. Role of ASXL1 mutations in myeloid malignancies
    Omar Abdel-Wahab; Fiscal Year: 2013
    ..Recently, recurrent mutations in ASXL1 were discovered in patients with myeloid malignancies, including myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and acute myeloid leukemia (AML)...
  30. p38 MAPK as a therapeutic target in Myelodysplastic syndrome
    Amit Verma; Fiscal Year: 2009
    b>Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and decreased blood counts...
  31. Comparative Effectiveness: Erythropoietic Stimulating Agents in Treatment of MDS
    Amy J Davidoff; Fiscal Year: 2010
    ..study will examine patterns of treatment with erythropoietic stimulating agents (ESA) in patients with myelodysplastic syndromes (MDS), and compare clinical benefits, risks, and costs associated with any ESA use, and different levels ..
  32. WHOLE GENOME SEQUENCING OF MYELODYSPLASTIC SYNDROMES
    Timothy A Graubert; Fiscal Year: 2010
    ..We will use whole genome resequencing to identify genetic changes relevant for the pathogenesis of Myelodysplastic Syndromes (MDS)...
  33. Synergestic roles of SRSF2 and RUNX1 in blood cell development and pathology
    Dong Er Zhang; Fiscal Year: 2013
    ..revealed prevalent mutations in splicing factor-encoded genes in bone marrow failure diseases, such as myelodysplastic syndromes (MDS) and related disorders...
  34. The role of the Musashi family in hematopoiesis
    Michael Kharas; Fiscal Year: 2013
    ..PUBLIC HEALTH RELEVANCE: Stem cell disorders comprise a large group of myelodysplastic syndromes, inherited and acquired bone failure syndromes such as aplastic anemias...
  35. Contribution of the vascular niche to the hematopoietic reconstitution.
    Shahin Rafii; Fiscal Year: 2012
    ..and HSC self-renewal will offer new strategies to treat BM failure states, including aplastic anemia, myelodysplastic syndromes and accelerate BM reconstitution after chemotherapy, irradiation and transplantation...
  36. Prediction of Response to Revlimid
    Azra Raza; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Myelodysplastic syndromes (MDS) constitute a group of heterogeneous bone marrow stem cell disorders where no single treatment strategy has been of universal benefit...
  37. Stem Cell Transplantation: Basic/Clinical Research
    Rainer F Storb; Fiscal Year: 2010
    ..research to improve treatment of patients with acquired and inherited nonmalignant blood disorders and myelodysplastic syndromes by hematopoietic cell transplantation (HCT)...
  38. Atg1 homologues in autophagy, mitochondrial degradation and erythroid maturation
    Mondira Kundu; Fiscal Year: 2010
    ..will provide the foundation for launching an independent academic career studying normal erythroid development and its relationship to hematological disorders, including myelodysplastic syndromes and acute leukemias. (End of Abstract)
  39. The role of microRNAs in leukemic initiation and maintenance
    Jun Lu; Fiscal Year: 2013
    ..to our own work, it has been reported that miR-125b-1 is translocated in a subgroup of human AMLs and myelodysplastic syndromes. The major goal of this proposal is to determine the roles of miR-125 family microRNAs in leukemic ..
  40. The Role of Telomere Shortening in MDS-AML Pathogenesis (resubmission)
    Mary Y Armanios; Fiscal Year: 2013
    ..Affected patients have an increased risk for developing hematologic malignancies, specifically myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)...
  41. Identification and characterization of genes in del(5q) myelodysplastic syndrome
    Daniel Starczynowski; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Myelodysplastic syndromes (MDS) are clonal marrow failure disorders defined by blood cytopenias due to ineffective hematopoiesis, genomic instability, and predisposition to leukemia...
  42. A model of myelodysplastic syndrome progression and leukemic stem cells
    Yupo Ma; Fiscal Year: 2012
    b>Myelodysplastic syndromes (MDS) are stem-cell malignancies most frequently seen among elderly patients, resulting in a high annual incidence of approximately 14,000 new cases per year...
  43. Translational Studies of Inherited Marrow Failure and Myelodysplastic Syndromes
    David A Williams; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): The inherited bone marrow failure and myelodysplastic syndromes (iBMF/MDS) are a heterogeneous group of disorders that are characterized by impaired hematopoiesis and a propensity to progress to ..
  44. 2013 CRTI Summer Workshop
    Julie A Panepinto; Fiscal Year: 2013
    ..all areas of hematology, including the hematological malignancies (leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, myeloproliferative neoplasms) and non-malignant hematology (bleeding and clotting disorders and ..
  45. Modulation of aged hematopoietic stem cell niches
    Laura M Calvi; Fiscal Year: 2013
    ..by applicant): Aging of the hematopoietic system results in an increased risk of developing cytopenias, Myelodysplastic syndromes (MDS), myeloproliferative disorders and leukemias...
  46. BIOCHEMICAL BASIS FOR THERAPEUTIC ACTIVITY
    WILLIAM K PLUNKETT; Fiscal Year: 2013
    ..Clinically active in phase I studies in relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes, Sapacitabine, the orally bioavailable form of 2'-C- cyano-2'-deoxy-1-2-D-arabino-..
  47. Clinical and Molecular Characterization of Familial Marrow Failure Syndrome
    Akiko Shimamura; Fiscal Year: 2012
    ..group of disorders characterized by marrow failure, congenital anomalies, and predisposition to myelodysplastic syndromes (MDS)...
  48. Targeted Therapy of Lyn in Myelodysplastic Syndrome
    SETH JOEL COREY; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Myelodysplastic Syndromes (MDS) are a disorder, increasing in frequency, for which there is poor understanding of its pathophysiology and no curative therapy short of an allogeneic stem cell ..
  49. MECHANISM OF GENE ACTIVATION BY DNA METHYLASE INHIBITORS
    Edward Newman; Fiscal Year: 2001
    ..in the treatment of acute myeloid leukemia and likely therapeutic utility in other leukemias and myelodysplastic syndromes. After incorporation into DNA, DAC inhibits the enzyme DNA (cytosine-5)-methyltransferase (MT'ase)...
  50. MECHANISM BASED PHASE I TRIAL OF TOPOTECAN IN LEUKEMIA
    Brenda Cooper; Fiscal Year: 2000
    ..enzyme topoisomerase I has shown activity in patients with relapsed, refractory leukemia, and myelodysplastic syndromes. The applicant's hypothesis is that improvements in remission rates in these patients are likely to ..
  51. AA&MDSIF Second Bone Marrow Failure Disease Scientific Symposium
    Richard Stone; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Aplastic anemia (AA), the myelodysplastic syndromes (MDS), and paroxysmal nocturnal hemoglobinuria (PNH) are rare diseases that all result in bone marrow failure...
  52. CLONALITY IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASIA
    Donald Kufe; Fiscal Year: 1992
    ..biological analysis of clonal growth and growth factor expression in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)...
  53. GENETIC ANALYSIS--DYSERYTHROPOIETIC ANEMIA IN ZEBRAFISH
    Barry Paw; Fiscal Year: 2000
    ..acquired anemias indicative of bone marrow stress, such as congenital dyserythropoietic anemias (CDA), myelodysplastic syndromes, leukemia megaloblastic anemia, HIV infection, recovery from bone marrow transplantation, and hemolytic ..
  54. The Role of Geminin in Hematopoiesis
    Thomas McGarry; Fiscal Year: 2009
    ..proliferation and differentiation underlie common hematological problems like leukemia, lymphoma, and myelodysplastic syndromes. Despite their obvious importance, the mechanisms that control the choice between continued cell ..
  55. Pathophysiology of thiamine-responsive anemia syndrome
    Ellis Neufeld; Fiscal Year: 2006
    ..The anemia of TRMA reveals both megaloblastic changes and ringed sideroblasts, reminiscent of acquired Myelodysplastic Syndromes. The bases of anemia, deafness and diabetes in TRMA are obscure...
  56. New Approaches to the Biology and Treatment of Myelodysplastic Syndromes (MDS)
    Hagop Kantarjian; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): The incidence of myelodysplastic syndromes (MDS) is likely to increase as the U.S. population ages. Nonetheless, there are no satisfactory treatments...
  57. Phase II trial of valproic acid in myelodysplasia
    Peter Klein; Fiscal Year: 2006
    The myelodysplastic syndromes (MDS) are a heterogeneous group of neoplastic hematopoietic stem cell disorders characterized by peripheral blood cytopenias and a proclivity for transformation into acute leukemia...
  58. G-CSF RECEPTOR ISOFORMS AND MYELOPOIESIS
    Scott White; Fiscal Year: 1999
    ..A better understanding of relative G-CSFR isoform expression will provide insight into a variety of disorders of myelopoiesis, such myelogenous leukemia or myelodysplastic syndromes.
  59. Vitamin D and Dexamethasone in Myelodysplastic Syndromes
    ROBERT REDNER; Fiscal Year: 2003
    The myelodysplastic syndromes (MDS) represent a heterogeneous group of diseases that manifest themselves as dyspoiesis...
  60. Are the effects of SIMPL on hematopoiesis seen in vitro translated in vivo?
    Maureen Harrington; Fiscal Year: 2009
    ..TNFa can deplete stem and progenitor cell numbers, a physiological state similar to what is seen in myelodysplastic syndromes, which are poised to evolve into leukemia...
  61. CELLULAR AND HUMORAL MODULATION OF HEMOPOIESIS
    Peter Greenberg; Fiscal Year: 1990
    ..in normal individuals and those with hemopoietic diseases, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)...
  62. TLS and TLS Fusion Proteins in Leukemia
    Liu Yang; Fiscal Year: 2005
    ..In acute myelogenous leukemia (AMIL), chronic myelogenous leukemia (CML) in blast crisis, and myelodysplastic syndromes, the TLS (translocation liposarcoma) gene is fused to the ERG (ets-related gene) gene through a ..